<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) have been reported only rarely following treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We report five patients treated for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> with chromosome 7 abnormalities, including -7, del(7)(q22q36) and del(7)(p11.22p22) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had been treated with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, topoisomerase 2 inhibitors and granulocyte or granulocyte-monocyte colony-stimulating factor and three with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> as part of autologous transplant regimens </plain></SENT>
<SENT sid="3" pm="."><plain>These cases further document t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> as a complication of therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Presence of chromosome 7 abnormalities in patients with and without prior <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> therapy suggests possible association with the <z:chebi fb="0" ids="35221">antimetabolite</z:chebi> <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
</text></document>